A new report by KPMG estimates clinical research supported by the National Institute for Health Research contributes £2.7 billion to the UK economy annually.
The analysis, commissioned by the NIHR clinical research network (CRN), covers the financial period 2016/17 to 2018/19 and presents amalgamated three-year data alongside figures for each individual financial year (FY). It shows that over the three-year period, clinical research supported by the NIHR CRN generated an estimated £8 billion in gross value added (GVA) and 47,467 full time equivalent (FTE) jobs for the UK.
The analysis also shows that for each patient recruited onto a NIHR CRN commercial trial, on average NHS providers in England receive an estimated £9,200 from life sciences companies, and save an estimated £5,800 per patient (where trial drugs replaced the standard treatment).
For the financial year 2018/19, the total estimated income for the NHS from delivering commercial clinical trials was £355 million, and the total estimated cost saving was £28.6 million.
Commenting on the figures, Dr Jonathan Sheffield OBE, Chief Executive of the NIHR CRN said: "The report highlights and evidences the significant contribution that the delivery of clinical research within the UK makes to the health and the wealth of the nation. Put simply, clinical research benefits our economy enormously, it creates jobs, and generates much needed income and savings for NHS trusts, ultimately helping NHS finances to go further while improving patient care and services through the development of new drugs and treatments.”